Equity Investment Corp Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Equity Investment Corp bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,681,360 shares of the medical equipment provider’s stock, valued at approximately $144,748,000. Zimmer Biomet accounts for 2.8% of Equity Investment Corp’s portfolio, making the stock its 11th largest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Main Management ETF Advisors LLC grew its holdings in Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after purchasing an additional 112 shares during the period. Citizens National Bank Trust Department raised its holdings in shares of Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 141 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Zimmer Biomet by 0.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after buying an additional 152 shares during the period. TD Private Client Wealth LLC lifted its holdings in Zimmer Biomet by 15.3% in the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after acquiring an additional 153 shares during the period. Finally, Leonteq Securities AG lifted its stake in shares of Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after purchasing an additional 153 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Trading Up 1.1%

Shares of ZBH opened at $99.31 on Wednesday. The stock has a market capitalization of $18.94 billion, a PE ratio of 24.16, a P/E/G ratio of 3.20 and a beta of 0.45. The company’s fifty day moving average is $91.91 and its 200 day moving average is $90.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the business earned $2.07 earnings per share. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Stifel Nicolaus lifted their target price on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Sanford C. Bernstein raised their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company decreased their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.